Serum free light chains testing in monoclonal gammopathies

Dr. Keren covers the clinical and laboratory aspects impacting serum free light chains testing in diagnosis and monitoring of monoclonal gammopathies, such as multiple myeloma. Since its introduction in 2002, serum free light chains (sFLC) testing has become a key laboratory parameter for diagnosis and management of monoclonal gammopathies. Currently, several assays for determination of sFLC assays are commercially available, of which some designs employ polyclonal antibodies and others use monoclonal antibodies.

David F. Keren, University of Michigan

Prof. David F. Keren, MD
Professor, Chemical Pathology
Medical Director of Phlebotomy Services
Department of Pathology
Michigan Medicine
University of Michigan
Ann Arbor, USA